BioSpace News Archive

GeneCentric Therapeutics announced today the completion of its Piedmont Study, conducted in collaboration with Atrium Health Levine Cancer Institute.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Amneal’s Co-Chief Executive Officer and President, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022 at 11:15 AM Eastern Time.

UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, today announced that the first patient has received their first dose in its home instillation study of UGN-102 in patients with low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).

EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene therapies and delivery solutions for liquid and solid tumors, today announced the completion of a $41 million Series B2 financing.

Emmes, a global, full-service Clinical Research Organization dedicated to supporting the advancement of public health and biopharmaceutical innovation and a portfolio company of Behrman Capital, announced that it has acquired Institut Dr. Schauerte, a CRO headquartered in Munich, Germany.

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that its collaboration partner, Kissei Pharmaceutical Co., Ltd. (“Kissei”), has released positive topline results from its Phase 3 clinical trial in Japan evaluating fostamatinib disodium hexahydrate for the treatment of adult chronic immune thrombocytopenia (ITP).

Arena Pharmaceuticals, Inc. announced that the Compensation Committee of its Board of Directors granted to 16 new employees 28,659 inducement restricted stock units.

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced it received CE mark of the Eversense® NOW Remote Monitoring App for the Android Operating System.

DermBiont announced today that it has raised a $28 million Series A2 financing in parallel with the acquisition of clinical-stage biotechnology company Chromaderm.

Neogen Corporation (NASDAQ: NEOG) announced today the results of the second quarter of its 2022 fiscal year, which ended November 30.